Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Seattle Genetics Inc (NASDAQ: SGEN) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Seattle Genetics Inc (NASDAQ: SGEN) concerning whether a series of statements by Seattle Genetics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On December 27, 2016, Seattle Genetics revealed that the U.S. Food and Drug Administration had placed a clinical hold or partial clinical hold on several early stage trials of its experimental cancer drug, vadastuximab talirine, to evaluate the potential risk of hepatotoxicity. The Company stated that six acute myeloid leukemia patients had been identified with liver toxicity and that four had died.

Following this news, NASDAQ: SGEN dropped causing investors harm.

Based in Bothell, Washington, and founded in 1998 Seattle Genetics Inc develops and commercializes targeted therapies for the treatment of cancer globally.

If you purchased shares of Seattle Genetics Inc (NASDAQ: SGEN) on or before December 27, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185